Betadine Cold Defense extension agreement with Marinomed – PR English – 26 Nov 2018

November 26, 2018 - 5 minutes read

Mundipharma set to provide innovative cold treatment for Adults and Children in new markets across the Middle East, Turkey and Africa region

16, January, Dubai: Mundipharma, the maker of the BETADINETM range of products, announced expansion of the partnership with Marinomed Biotech to extend their rights for the Carragalose® based Nasal Sprays and Lozenges in additional markets across the Middle East, Turkey and Africa (META).

The deal will aim to further extend marketing of Marinomed’s products which have shown to significantly reduce disease duration and reduce relapses and help more adults and children suffering from the symptoms of the disease in additional markets across the META region.
The common cold is a viral infection that affects adults twice per year on average. The impact is greater for children who can typically contract them up to five to seven times per year due to their exposure at school and the playground.
The new BETADINETM COLD DEFENCE is a natural product with anti-viral effects that helps reduce duration of colds in adults and children.1-4 It is delivered as a nasal spray and contains the ingredient iota-carrageenan, also called Carragelose®. It is available in adult and children’s formulations and is recommended for use at the first sign of cold symptoms.
Several large scale clinical trials involving close to 600 adult and pediatric patients were conducted to evaluate the efficacy and safety of the nasal spray. The analysis of children and adults suffering from virus-confirmed common cold after two randomized, double-blind, placebo-controlled trials the nasal spray appeared as an effective treatment of common cold.1-4
Ashraf Allam, Vice President of Mundipharma Middle East, Turkey & Africa said “Every year the common cold and flu negatively impact lives of the families. BETADINETM COLD DEFENCE will help adults and children1-4 overcome the early symptoms of cold and may prevent the progression of the disease.

“Making BETADINETM COLD DEFENCE range accessible in other countries across META region is a part of Mundipharma’s commitment of making the latest and most effective treatments available to our patients and help families lead a healthier, happier life” – he added.

TM: BETADINE is a Registered Trademark of Mundipharma.
® : Carregelose is a Registered Trademark of Marinomed.

About Mundipharma
Mundipharma and its network of privately owned Independent Associated Companies (IACs) is dedicated to alleviating human suffering and improving quality of life for the human race. The Mundipharma story, spanning over six decades brings together a visionary approach and a pioneering spirit – what is best told through its patients, employees and the communities across six continents in which they serve. Mundipharma is focused on business transformation by leveraging global leadership in pain and, through a shared spirit of innovation, building a growing presence in antisepsis, respiratory, oncology, ophthalmology, consumer healthcare and other specialty areas.

For more information, please visit: www.mundipharma.ae

For more information, please contact:
Mundipharma META
Patrycja Czoch, Corporate Communications Manager
Mob: +97 1 50 85 12 700
Patrycja.Czoch@mundipharma.ae

1. ‘Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold’, Tamas Fazekas, Philipp Eickhoff, Nathalie Pruckner, Georg Vollnhofer, Gustav Fischmeister, Christopher Diakos, Margit Rauch, Maria Verdianz, Andreas Zoubek, Helmut Gadner and Thomas Lion, BMC Complementary and Alternative Medicine, The official journal of the International Society for Complementary Medicine. Published, 5 September 2012.
2.Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trial. Ludwig et al. Respiratory Research 2013, 14:124
3. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Eccles et al. Respiratory Research 2010, 11:108
4. Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials. Koenighofer et al. Multidisciplinary Respiratory Medicine 2014, 9:57

Tags: